Diyong Xu, Director, 10% Owner at Q32 Bio Inc. (QTTB), bought 1,875,000 shares at $8.00 ($15.0M) on 2026-05-28, disclosed to the SEC on 2026-06-01.
Director Diyong Xu executed the largest insider purchase in Q32 Bio's history by buying $10 million worth of shares at $8.00, signaling strong conviction in the biotech's recent momentum and pipeline progress. This significant capital commitment comes as the stock approaches an 18-month high and follows a successful $55 million private placement.
Q32 Bio is trading at $6.69, sitting 14.23% below its 52-week high of $7.80, despite a strong 90-day gain of 36.81% and a 1-year surge of 286.71%.
A $55 million private placement announced on May 27, 2026, provides capital for the alopecia areata pipeline; additionally, SIGNAL-AA study data is expected mid-2026.
The stock carries a short interest of 7.77% of the float, indicating potential volatility if the bullish thesis falters. Furthermore, the company trades at a negative forward P/E of -2.18, reflecting current losses that must be addressed for long-term sustainability.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.00 | 625,000 | $5.0M | 33.3% |
| 2 | $8.00 | 1,250,000 | $10.0M | 66.7% |
| Total | $8.00 avg | 1,875,000 | $15.0M | 100% |